Immunome, a Wynnewood, PA-based discovery-stage antibody platform company focused on life-threatening infectious diseases, completed an undisclosed equity financing.
Investors include BioAdvance, the Biotechnology Greenhouse of Southeastern Pennsylvania and other private investors.
As also stated by Tim Pelura, president and CEO of the company, this financing will enable Immunome to identify its first therapeutic candidate for serious infectious diseases utilizing its monoclonal antibody technology.
FinSMEs
24/05/2010